ABSTRACT Background Plasma tumour DNA (ptDNA) levels on treatment are associated
with response in a variety of cancers. However, the role of ptDNA in prostate cancer …

The linear mRNAs transcribed under alternative RNA splicing and overexpression/
amplification of the androgen receptor (AR) gene are poor prognostic biomarkers of castrate …

Purpose: In metastatic castration-resistant prostate cancer (mCRPC) low serum androgens
prior to starting abiraterone acetate (AA) is associated with more rapid progression. We …

In patients with metastatic castrate‐resistant prostate cancer (mCRPC), circulating tumor
DNA (ctDNA) analysis offers novel opportunities for the development of non‐invasive …

Background: Circulating tumor cells (CTC), androgen receptor full-length (AR-FL), and
androgen receptor splice variant 7 (AR-V7) are prognostic in patients (pts) with metastatic …

Liquid biopsies have been receiving tremendous attentions as easy, rapid, and non-invasive
tools for cancer diagnosis. Liquid biopsy can be performed repeatedly for disease …

The therapeutic landscape of metastatic hormone sensitive and metastatic castration-
resistant prostate cancer (mCRPC) is rapidly changing. We reviewed the current treatment …

Although prostate cancer (PCa) is one of the most common tumors in European males, the
only minimally invasive diagnostic tool in PCa setup is the determination of PSA in serum …

Background Plasma androgen receptor (AR) copy number status has been identified as a
potential biomarker of response in patients with metastatic castration-resistant prostate …

Abstract Background In a Phase 2 clinical trial, we aimed to determine the lutetium-177
[177Lu]-PSMA-617 activity and the clinical utility of levels of plasma androgen receptor (AR) …